Compare LYG & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYG | BMY |
|---|---|---|
| Founded | 1695 | 1887 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5B | 113.5B |
| IPO Year | 2012 | 2006 |
| Metric | LYG | BMY |
|---|---|---|
| Price | $6.04 | $67.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 15 |
| Target Price | N/A | ★ $61.73 |
| AVG Volume (30 Days) | ★ 13.0M | 11.3M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 3.73% | ★ 4.38% |
| EPS Growth | N/A | ★ 178.46 |
| EPS | N/A | ★ 2.93 |
| Revenue | N/A | ★ $48,194,000,000.00 |
| Revenue This Year | $13.36 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $62.13 | ★ $23.18 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.20 | $42.52 |
| 52 Week High | $6.34 | $68.64 |
| Indicator | LYG | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 64.48 |
| Support Level | $5.84 | $56.46 |
| Resistance Level | $6.18 | $68.37 |
| Average True Range (ATR) | 0.07 | 1.39 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 39.89 | 82.89 |
Lloyds is a retail and commercial bank headquartered in the United Kingdom. The bank operates via three business segments: retail, commercial banking, and insurance and wealth. In retail, Lloyds offers primarily mortgages (66% of its loan portfolio), credit cards, and current accounts to its customers. Its commercial banking operation provides lending, transaction banking, working capital management, and debt capital market services to large companies and financial institutions in the UK. Insurance and wealth round out the product lineup with life and property insurance as well as pension solutions and high-net-worth asset management services.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.